Visanne Post-approval Observational Study (VIPOS)

Center for Epidemiology and Health Research, Germany

Status: Completed

Conditions: Endometriosis

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01266421

ZEG2010_03

Details and patient eligibility

About

The study assesses safety aspects of Dienogest (DNG) 2mg/day (Visanne) used as endometriosis therapy and of other hormonal treatments for endometriosis.

Full description

Endometriosis is a common, chronic, gynecological disease characterized by pain and impaired fertility. It causes chronic inflammation, ovarian cyst formation, fibrosis and adhesions. Symptoms seem to respond to decreased circulating estrogen. The mainstay of medical treatment is hormonal induced anovulation and a reduction in endogenous estrogen production.

Medications for endometriosis such as Danazol and GnRH agonists have clinically relevant side-effects limiting treatment duration with these medications to 6-12 months.

Dienogest (DNG) is a 19-nortestosterone derivative progestogen. DNG 2mg/day is a reliable and effective treatment for dysmenorrhea, premenstrual pain, dyspareunia and diffuse pelvic pain associated with endometriosis.

Two important class effects of progestogens are the induction of bleeding disturbances and their influence on mood disturbance. It is not known what influence DNG will have on bleeding disturbances associated with endometriosis, particularly over a longer time frame.

In addition, women who suffer from endometriosis are at high risk of developing depressive symptoms. It is difficult to differentiate if depressive symptoms are causally associated with progestogen use or sequela of the disease process.

This study investigates the safety of DNG for endometriosis with regard to medical interventions for anemia and worsening of depressive symptoms associated with the disease. It is a prospective, controlled, non-interventional cohort study with two cohorts: users of DNG and users of other medications for the treatment of endometriosis. The study will be implemented in several European countries.

Enrollment: 27,840 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women using a newly prescribed regimen for endometriosis (first-time users or switchers or re-starters)
• Women who are willing to participate in this long-term follow-up study

Exclusion criteria

• Women who are not cooperative/available for follow-up
• Women with a language barrier

Trial design

27,840 participants in 3 patient groups

Dienogest (DNG)

Description:

Women using DNG) for the treatment of endometriosis

Other approved endometriosis drugs (OAED)

Description:

Women using hormonal medications approved for endometriosis treatment in all particiapting countries other than DNG.

Non-approved endometriosis drugs (NAED)

Description:

Women using hormonal medications not approved for endometriosis treatment in all particiapting countries.